Search Results - "Bernhard Landwehrmeyer, G."

Refine Results
  1. 1
  2. 2
  3. 3
  4. 4

    Speech biomarkers in Huntington's disease: A cross‐sectional study in pre‐symptomatic, prodromal and early manifest stages by Kouba, Tomas, Frank, Wiebke, Tykalova, Tereza, Mühlbäck, Alzbeta, Klempíř, Jiří, Lindenberg, Katrin S., Landwehrmeyer, G. Bernhard, Rusz, Jan

    Published in European journal of neurology (01-05-2023)
    “…Background and purpose Motor speech alterations are a prominent feature of clinically manifest Huntington's disease (HD). Objective acoustic analysis of speech…”
    Get full text
    Journal Article
  5. 5
  6. 6

    Huntingtin HTT1a is generated in a CAG repeat-length-dependent manner in human tissues by Hoschek, Franziska, Natan, Julia, Wagner, Maximilian, Sathasivam, Kirupa, Abdelmoez, Alshaimaa, von Einem, Björn, Bates, Gillian P, Landwehrmeyer, G Bernhard, Neueder, Andreas

    Published in Molecular medicine (Cambridge, Mass.) (08-03-2024)
    “…The disease-causing mutation in Huntington disease (HD) is a CAG trinucleotide expansion in the huntingtin (HTT) gene. The mutated CAG tract results in the…”
    Get full text
    Journal Article
  7. 7

    Suicidal ideation and suicidal behavior according to the C-SSRS in a European cohort of Huntington's disease gene expansion carriers by van Duijn, Erik, Vrijmoeth, Eslie M., Giltay, Erik J., Bernhard Landwehrmeyer, G.

    Published in Journal of affective disorders (01-03-2018)
    “…Huntington's disease (HD) gene expansion carriers are at an increased risk of suicide, but so far, no studies have investigated the full spectrum of…”
    Get full text
    Journal Article
  8. 8

    Ubiquitination and the proteasome rather than caspase‐3‐mediated C‐terminal cleavage are involved in the EAAT2 degradation by staurosporine‐induced cellular stress by Voss, Timo‐Daniel, Gerget, Maria, Linkus, Birgit, Einem, Bjoern, Landwehrmeyer, G. Bernhard, Lewerenz, Jan

    Published in Journal of neurochemistry (01-05-2021)
    “…Diminished glutamate (Glu) uptake via the excitatory amino acid transporter EAAT2, which normally accounts for ~90% of total forebrain EAAT activity, may…”
    Get full text
    Journal Article
  9. 9
  10. 10
  11. 11
  12. 12
  13. 13

    A greatly extended PPARGC1A genomic locus encodes several new brain-specific isoforms and influences Huntington disease age of onset by SOYAL, Selma M, FELDER, Thomas K, AUER, Simon, HAHNE, Penelope, OBERKOFLER, Hannes, WITTING, Anke, PAULMICHL, Markus, BERNHARD LANDWEHRMEYER, G, WEYDT, Patrick, PATSCH, Wolfgang

    Published in Human molecular genetics (01-08-2012)
    “…PGC-1α has been implicated in the pathogenesis of neurodegenerative disorders. Several single-nucleotide polymorphisms (SNPs) located in two separate haplotype…”
    Get full text
    Journal Article
  14. 14

    Overlap between age-at-onset and disease-progression determinants in Huntington disease by Aziz, N Ahmad, van der Burg, Jorien M.M, Tabrizi, Sarah J, Landwehrmeyer, G Bernhard

    Published in Neurology (12-06-2018)
    “…OBJECTIVEA fundamental but still unresolved issue regarding Huntington disease (HD) pathogenesis is whether the factors that determine age at onset are the…”
    Get full text
    Journal Article
  15. 15

    HAP40 protein levels are huntingtin-dependent and decrease in Huntington disease by Huang, Bin, Seefelder, Manuel, Buck, Eva, Engler, Tatjana, Lindenberg, Katrin S., Klein, Fabrice, Landwehrmeyer, G. Bernhard, Kochanek, Stefan

    Published in Neurobiology of disease (01-10-2021)
    “…The huntingtin-associated protein 40 (HAP40) is an abundant interactor of huntingtin (HTT). In complexes of these proteins, HAP40 tightly binds to HTT in a…”
    Get full text
    Journal Article
  16. 16

    Riluzole in Huntington's disease: a 3-year, randomized controlled study by Landwehrmeyer, G. Bernhard, Dubois, Bruno, de Yébenes, Justo Garcia, Kremer, Berry, Gaus, Wilhelm, Kraus, Peter H., Przuntek, Horst, Dib, Michel, Doble, Adam, Fischer, Wilhelm, Ludolph, Albert C.

    Published in Annals of neurology (01-09-2007)
    “…Objective We conducted a randomized double‐blind trial of riluzole in Huntington's disease to investigate the efficacy of this antiexcitotoxic drug in slowing…”
    Get full text
    Journal Article
  17. 17

    How to Arrange Follow-Up Time-Intervals for Longitudinal Brain MRI Studies in Neurodegenerative Diseases by Müller, Hans-Peter, Behler, Anna, Landwehrmeyer, G. Bernhard, Huppertz, Hans-Jürgen, Kassubek, Jan

    Published in Frontiers in neuroscience (15-07-2021)
    “…Background: Longitudinal brain MRI monitoring in neurodegeneration potentially provides substantial insights into the temporal dynamics of the underlying…”
    Get full text
    Journal Article
  18. 18

    Enroll-HD: An Integrated Clinical Research Platform and Worldwide Observational Study for Huntington's Disease by Sathe, Swati, Ware, Jen, Levey, Jamie, Neacy, Eileen, Blumenstein, Robi, Noble, Simon, Mühlbäck, Alzbeta, Rosser, Anne, Landwehrmeyer, G Bernhard, Sampaio, Cristina

    Published in Frontiers in neurology (18-08-2021)
    “…Established in July 2012, Enroll-HD is both an integrated clinical research platform and a worldwide observational study designed to meet the clinical research…”
    Get full text
    Journal Article
  19. 19

    Fast-to-Slow Transition of Skeletal Muscle Contractile Function and Corresponding Changes in Myosin Heavy and Light Chain Formation in the R6/2 Mouse Model of Huntington's Disease by Hering, Tanja, Braubach, Peter, Landwehrmeyer, G Bernhard, Lindenberg, Katrin S, Melzer, Werner

    Published in PloS one (07-11-2016)
    “…Huntington´s disease (HD) is a hereditary neurodegenerative disease resulting from an expanded polyglutamine sequence (poly-Q) in the protein huntingtin (HTT)…”
    Get full text
    Journal Article
  20. 20